DrugPatentWatch Database Preview

Ariad Company Profile

« Back to Dashboard

What is the competitive landscape for ARIAD, and when can generic versions of ARIAD drugs launch?

ARIAD has two approved drugs.

There are six US patents protecting ARIAD drugs.

There are one hundred and one patent family members on ARIAD drugs in twenty-three countries and sixteen supplementary protection certificates in fourteen countries.

Summary for Ariad

International Patents:	101
US Patents:	6
Tradenames:	2
Ingredients:	2
NDAs:	2
Patent Litigation for Ariad:	See patent lawsuits for Ariad

Drugs and US Patents for Ariad

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ariad	ALUNBRIG	brigatinib	TABLET;ORAL	208772-003	Oct 2, 2017		RX	Yes	Yes	9,012,462			Y
Ariad	ALUNBRIG	brigatinib	TABLET;ORAL	208772-002	Apr 28, 2017		RX	Yes	No	9,611,283
Ariad	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-002	Dec 14, 2012		RX	Yes	Yes

International Patents for Ariad Drugs

Country	Patent Number	Estimated Expiration
Japan	2018168191
Israel	229351
Japan	2017186345

Supplementary Protection Certificates for Ariad Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1973545	122013000152	Germany		PRODUCT NAME: PONATINIB "BENZAMID, 3-(2-IMIDAZO(1,2-B)PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-(4-((4-METHYL-1-PIPERAZINYL)METHYL)-3-(TRIFLUORMETHYL)PHENYL)"; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
1973545	151 5025-2013	Slovakia		(93) EU/1/13/839/001, EU/1/13/839/002, EU/1/13/839/003, EU/1/13/839/004, 1.7.2013, EU (94) 3.7.2028
1973545	490	Finland

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Ariad